BPI has inaugurated a modern freeze-dryer machine and unveiled the BPI Pharmaceutical Museum on 14 August, intending to bolster anti-snake venom production using the freeze-drying system in the coming years.
The State-owned pharmaceutical factory (Insein) (BPI) is poised to enhance its production of novel anti-COVID medications while continuing the freeze-drying of anti-snake venom in the upcoming year.
BPI has significantly expanded its pharmaceutical production network, encompassing branches like the pharmaceutical factories in Ywathagyi, Inyaung, PyinOoLwin, and Sagaing. Other components include the Anti-Snake Venom Production Branch in Hmawby, the Horse Ranches in Myitchay, Yanpel, and Heho, the Tatmadaw Pharmaceuticals Factory (Hmawby), and the Universities of Pharmacy in Yangon and Mandalay. These enclose the Pharmaceutical Factory (Insein) and the Research Unit.
Furthermore, BPI has inaugurated a modern freeze-dryer machine and unveiled the BPI Pharmaceutical Museum on 14 August, intending to bolster anti-snake venom production using the freeze-drying system in the coming years. The establishment of the BPI Pharmaceutical Museum aims to preserve over six decades of pharmaceutical production experience, equipment, methods, important medical literature, and the legacy of pharmaceutical manufacturing by a Myanmar State-owned enterprise.
The production of anti-snake venom has demonstrated a consistent increase. With 60,000 units manufactured last year, the figure has surged to 80,000 this year. — TWA/CT
